Distinguished in Cerebrotendinous Xanthomatosis

William J. Griffiths

Grove Building, Singleton Park, 
Swansea, WLS, GB 
Distinguished in Cerebrotendinous Xanthomatosis
Grove Building, Singleton Park, 
Swansea, WLS, GB 
OverviewLocationsClinical Research

Overview

William Griffiths practices in Swansea, United Kingdom. Mr. Griffiths is rated as a Distinguished expert by MediFind in the treatment of Cerebrotendinous Xanthomatosis. His top areas of expertise are Smith-Lemli-Opitz Syndrome, Cerebrotendinous Xanthomatosis, Xanthoma, Spastic Paraplegia Type 5A, and Liver Transplant.

His clinical research consists of co-authoring 122 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 9 articles in the study of Cerebrotendinous Xanthomatosis.

Gender
Male

Locations

Grove Building, Singleton Park, Swansea, WLS, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Pilot Open Label, Multi-dose, Phase 2 Study to Assess the Safety and Efficacy of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
A Pilot Open Label, Multi-dose, Phase 2 Study to Assess the Safety and Efficacy of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Randomized, Rater-Blinded, Multi-Center Study to Evaluate the Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease Aged 12 Years and Older, With an Extension Period of up to 60 Months
A Phase 3, Randomized, Rater-Blinded, Multi-Center Study to Evaluate the Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease Aged 12 Years and Older, With an Extension Period of up to 60 Months
Enrollment Status: Terminated
Publish Date: June 17, 2024
Intervention Type: Drug
Study Drug: ALXN1840
Study Phase: Phase 3
View 1 Less Clinical Trial

122 Total Publications

Sterol imbalances and cholesterol-24-hydroxylase dysregulation is linked to the underlying progression of multiple sclerosis.
Sterol imbalances and cholesterol-24-hydroxylase dysregulation is linked to the underlying progression of multiple sclerosis.
Journal: Brain pathology (Zurich, Switzerland)
Published: September 02, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Griffiths's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 30 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile